Propel Bio Management, LLC / CRNX
Propel Bio Management, LLC’s Crinetics Pharmaceuticals In Position
Does Propel Bio Management, LLC own Crinetics Pharmaceuticals In (CRNX)? Not currently — the last reported position was 165.0K shares worth $6M in Q4 2023; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$6M
Q4 2023
Shares
165.0K
% of Portfolio
+4.87%
Quarters Held
1
position exited
Position History CRNX
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q4 2023 | 165.0K | $6M | +4.87% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Propel Bio Management, LLC’s full portfolio or all institutional holders of CRNX.